The impact of re-excision and residual disease on local recurrence after breast conservation treatment for patients with early stage breast cancer.

Abstract:

UNLABELLED:The current study examined the impact of re-excision and residual disease on local recurrence after breast conservation treatment for patients with negative margins. Patients with residual disease on re-excision had a higher local recurrence rate than other patients. However, with reasonably low local recurrence rates in all subgroups, neither re-excision nor residual disease on re-excision are contraindications for breast conservation treatment. PURPOSE:To evaluate the impact of re-excision and the presence of residual disease on local recurrence for patients who underwent breast conservation treatment (BCT) with negative final resection margins. METHODS:The records of 902 patients with stage I or II unilateral invasive breast cancer who had BCT were reviewed. The study cohort consisted of patients with negative final resection margins and was divided into 3 subgroups: (a) single excision (n = 332 [37%]), (b) re-excision with no residual disease in the re-excision specimen (n = 440 [49%]), and (c) re-excision with residual disease in the re-excision specimen (n = 130 [14%]). The median follow-up was 6.75 years. RESULTS:At 15 years, the rates of local failure were 10% for patients with a single excision, 10% for patients with a re-excision without residual disease, and 16% for patients with a re-excision with residual disease (P = .033). There were no significant differences between the 3 groups for overall survival, cause-specific survival, relapse-free survival, or freedom from distant metastases (all P ≥ .082). Multivariate analysis demonstrated an increased risk of local failure for patients with residual disease in the re-excision specimen that was borderline statistically significant (hazard ratio, 2.16; P = .061). CONCLUSIONS:Despite achieving negative final resection margins, the patients with residual disease in the re-excision specimen had a higher rate of local recurrence than patients who underwent single excision or patients without residual disease on re-excision. However, local recurrence was reasonably low in all 3 subgroups, and, therefore, neither re-excision nor residual disease represent contraindications for BCT.

journal_name

Clin Breast Cancer

journal_title

Clinical breast cancer

authors

Ali AN,Vapiwala N,Guo M,Hwang WT,Harris EE,Solin LJ

doi

10.1016/j.clbc.2011.08.003

subject

Has Abstract

pub_date

2011-12-01 00:00:00

pages

400-5

issue

6

eissn

1526-8209

issn

1938-0666

pii

S1526-8209(11)00160-1

journal_volume

11

pub_type

杂志文章
  • Development and Validation of a Preoperative Scoring System to Distinguish Between Nonadvanced and Advanced Axillary Lymph Node Metastasis in Patients With Early-stage Breast Cancer.

    abstract:BACKGROUND:It has been determined that axillary lymph node dissection after the detection of limited axillary lymph node metastasis does not improve the prognosis of patients with breast cancer. Thus, a need exists for less-invasive axillary surgery. However, it remains unclear whether a predictive model based on preop...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.11.008

    authors: Murata T,Watase C,Shiino S,Jimbo K,Iwamoto E,Yoshida M,Takayama S,Suto A

    更新日期:2020-11-17 00:00:00

  • Radiotherapy in Patients 70 Years and Older With Triple-Negative Breast Cancer.

    abstract:PURPOSE:To evaluate the use of radiotherapy (RT) in older patients with triple-negative breast cancer (TNBC). PATIENTS AND METHODS:The National Cancer Data Base (NCDB) is a comprehensive national database that captures approximately 70% of newly diagnosed cancer patients in the United States. Data for patients meeting...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2016.05.011

    authors: Algan O,Zhao YD,Herman T

    更新日期:2016-08-01 00:00:00

  • Advances in radiation treatments of breast cancer.

    abstract::During the past decade, improvements in treatment-planning tools, computer and imaging technologies, and new therapeutic modalities have allowed radiation to be delivered in a conformal fashion while minimizing treatment toxicity. It is important that physicians involved in breast cancer treatment recognize the numero...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2004.n.002

    authors: Frank SJ,McNeese MD,Strom EA,Perkins G,Salehpour M,Schechter N,Buchholz TA

    更新日期:2004-02-01 00:00:00

  • Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.

    abstract:BACKGROUND:Triple-negative breast cancer (TNBC) is an aggressive disease without established targeted treatment options for patients with metastatic disease. This study was undertaken to evaluate potentially actionable biomarkers in a large cohort of TNBC and compare them with non-TNBCs. MATERIALS AND METHODS:We evalu...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.04.008

    authors: Millis SZ,Gatalica Z,Winkler J,Vranic S,Kimbrough J,Reddy S,O'Shaughnessy JA

    更新日期:2015-12-01 00:00:00

  • Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.

    abstract:BACKGROUND:Based on preclinical studies and a phase I trial of the combination of bortezomib and pegylated liposomal doxorubicin (PLD), which both showed activity in breast cancer, we conducted a phase II study of this regimen in patients with metastatic breast cancer. PATIENTS AND METHODS:Patients received bortezomib...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2010.n.061

    authors: Irvin WJ Jr,Orlowski RZ,Chiu WK,Carey LA,Collichio FA,Bernard PS,Stijleman IJ,Perou C,Ivanova A,Dees EC

    更新日期:2010-12-01 00:00:00

  • Effects of DNA ploidy and S-phase fraction on fluorine-18 FDG uptake of primary breast cancer lesions.

    abstract:BACKGROUND:Flow cytometry (FCM) evaluating DNA content is emerging as the tool to monitor cell proliferation and malignant potential in several cancers such as stomach, lung, and salivary gland tumor. The purpose of this study was to correlate (18)F-FDG uptake of dual-time-point (DTP) positron emission tomography (PET)...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2012.09.010

    authors: Kim DW,Kim CG

    更新日期:2013-06-01 00:00:00

  • CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2- Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

    abstract:BACKGROUND:This meta-analysis of randomized controlled trials aimed to comprehensively assess the efficacy and toxicity of cyclin-dependent kinase (CDK) 4/6 inhibitors in advanced breast cancer (ABC) with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) disease. METHODS:We ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clbc.2018.04.017

    authors: Deng Y,Ma G,Li W,Wang T,Zhao Y,Wu Q

    更新日期:2018-10-01 00:00:00

  • Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration.

    abstract:BACKGROUND:Postmenopausal women with osteoporosis had a 66% relative risk reduction for invasive breast cancer over 8 years of raloxifene therapy in the randomized, placebo-controlled 4-year MORE (Multiple Outcomes of Raloxifene Evaluation) trial and the CORE (Continuing Outcomes Relevant to Evista) trial, a 4-year fol...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3816/CBC.2009.n.008

    authors: Vogel VG,Qu Y,Wong M,Mitchell B,Mershon JL

    更新日期:2009-02-01 00:00:00

  • A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).

    abstract:BACKGROUND:Novel targeted agents and combinations have become available in multiple lines of treatment for human epidermal growth factor receptor 2-positive (HER2(+)) metastatic breast cancer (MBC). In this context, alternatives to the lapatinib (L) and capecitabine (C) regimen, evaluating L combined with other cytotox...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clbc.2015.10.005

    authors: Gómez HL,Neciosup S,Tosello C,Mano M,Bines J,Ismael G,Santi PX,Pinczowski H,Nerón Y,Fanelli M,Fein L,Sampaio C,Lerzo G,Capó A,Zarba JJ,Blajman C,Varela MS,Martínez-Mesa J,Werutsky G,Barrios CH

    更新日期:2016-02-01 00:00:00

  • Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.

    abstract:BACKGROUND:We investigated the effect of basal protein expression on trastuzamab response in patients with HER2-positive (HER2(+)) breast cancer who received trastuzamab (T) and in HER2(+) breast cancer cell lines. PATIENTS AND METHODS:Expression of cytokeratin (CK) 5/6, CK14, and epidermal growth factor receptor (EGF...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.06.001

    authors: Chung A,Choi M,Han BC,Bose S,Zhang X,Medina-Kauwe L,Sims J,Murali R,Taguiam M,Varda M,Schiff R,Giuliano A,Cui X

    更新日期:2015-12-01 00:00:00

  • Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

    abstract:BACKGROUND:The ExteNET trial demonstrated improved invasive disease-free survival (iDFS) with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, versus placebo in patients with human epidermal growth factor receptor 2-positive (HER2+)/hormone receptor-positive (HR+) early-stage breast cancer (eBC). PATIENTS...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.09.014

    authors: Chan A,Moy B,Mansi J,Ejlertsen B,Holmes FA,Chia S,Iwata H,Gnant M,Loibl S,Barrios CH,Somali I,Smichkoska S,Martinez N,Alonso MG,Link JS,Mayer IA,Cold S,Murillo SM,Senecal F,Inoue K,Ruiz-Borrego M,Hui R,Dendulu

    更新日期:2020-10-06 00:00:00

  • Comparison of HER2 detection methods between central and regional laboratories in Greece.

    abstract:PURPOSE:HER2 gene amplification and overexpression is associated with aggressive breast cancer and poor prognosis. Accurate HER2 testing of patients with breast cancer before treatment is important to ensure that as many patients with HER2-positive breast cancer as possible receive the most appropriate treatment and th...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2007.n.040

    authors: Papadopoulos S,Kouvatseas G,Skarlos D,Malamos N,Delliou E,Saratsiotou I,Ardavanis A,Mavroudis D,Skarpidi E,Arapantoni P,Karyda I,Patakioyta F,Aravantinos G,Razis E,Fountzilas G,Kosmidis P

    更新日期:2007-10-01 00:00:00

  • BRCA mutations and the risk of angiosarcoma after breast cancer treatment.

    abstract::Post-breast cancer treatment-related angiosarcomas were first observed in lymphedematous extremities after mastectomy and are now being reported with increasing frequency after lumpectomy and radiation. A case history is presented of a BRCA2 carrier who had a postmastectomy chest wall angiosarcoma but had neither ther...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2008.n.066

    authors: West JG,Weitzel JN,Tao ML,Carpenter M,West JE,Fanning C

    更新日期:2008-12-01 00:00:00

  • Equivalent Survival With Mastectomy or Breast-conserving Surgery Plus Radiation in Young Women Aged < 40 Years With Early-Stage Breast Cancer: A National Registry-based Stage-by-Stage Comparison.

    abstract:BACKGROUND:Studies have shown that young patients with early-stage breast cancer (BC) are increasingly undergoing mastectomy instead of breast-conserving therapy (BCT) consisting of lumpectomy and radiation. We examined the difference in outcomes in young women (aged < 40 years) who had undergone BCT versus mastectomy....

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.03.012

    authors: Ye JC,Yan W,Christos PJ,Nori D,Ravi A

    更新日期:2015-10-01 00:00:00

  • Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care.

    abstract:INTRODUCTION:Ensuring guideline-concordant cancer care is a Department of Veterans Affairs (VA) priority, especially as the number of breast cancer patients at VA medical centers (VAMCs) grows. We assessed the utilization and clinical impact of the 21-gene Recurrence Score test, which predicts 10-year risk of breast ca...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2017.11.018

    authors: Hull LE,Lynch JA,Berse BB,DuVall SL,Chun DS,Venne VL,Efimova OV,Icardi MS,Kelley MJ

    更新日期:2018-04-01 00:00:00

  • Predicting Brain Metastasis in Breast Cancer Patients: Stage Versus Biology.

    abstract:BACKGROUND:Brain metastasis (BM) is a life-threatening event in breast cancer patients. Identifying patients at a high risk for BM can help to adopt screening programs and test preventive interventions. We tried to identify the incidence of BM in different stages and subtypes of breast cancer. PATIENTS AND METHODS:We ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2017.08.004

    authors: Azim HA,Abdel-Malek R,Kassem L

    更新日期:2018-04-01 00:00:00

  • Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.

    abstract:PURPOSE:In order to evaluate the feasibility of dose-dense docetaxel followed by dose-dense AC (doxorubicin/cyclophosphamide) as adjuvant chemotherapy for operable breast cancer, we conducted a phase II study. PATIENTS AND METHODS:In cohort 1, 28 patients received docetaxel 100 mg/m2 followed by doxorubicin 60 mg/m2 w...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2007.n.029

    authors: Lambert-Falls R,Modugno S

    更新日期:2007-08-01 00:00:00

  • Role of Overweight, Obesity, and Comorbidities in the Prognosis of Patients With Breast Cancer With Brain Metastases.

    abstract:INTRODUCTION:Breast cancer (BC) is the most common cancer in women, and the incidence of brain metastasis (BM) from BC ranges from 20% to 30%, with a median survival of 10 to 15 months. Previous reports have shown that the presence of obesity or diabetes negatively impacts survival. The present study investigates the a...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clbc.2018.12.018

    authors: Cacho-Díaz B,Spínola-Maroño H,Reynoso N,González-Aguilar A,Mohar-Betancourt A

    更新日期:2019-04-01 00:00:00

  • Ductal carcinoma in situ of the breast in men: a review.

    abstract::Breast carcinoma in men is rare and comprises approximately 1% of all breast cancer cases. In contrast to the increase in the detection rate of ductal carcinoma in situ (DCIS) in women resulting from the wide use of screening mammography programs, the rate of male DCIS is still small and represents approximately 5% of...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CBC.2005.n.033

    authors: Pappo I,Wasserman I,Halevy A

    更新日期:2005-10-01 00:00:00

  • Delayed resolution of jaundice in the arm of a patient with impaired lymphatic drainage: a case report.

    abstract::A 40-year-old woman, 6 years after mastectomy, lymph node dissection, and locoregional radiation, presented with hepatic metastases, pruritus, and jaundice. Physical examination revealed uniformly jaundiced skin and no arm lymphedema. Ultrasonography confirmed progressive hepatic metastases with no evidence of intrahe...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2007.n.055

    authors: Tsang RY,Mackey JR

    更新日期:2007-12-01 00:00:00

  • Method of primary tumor detection as a risk factor for local and distant recurrence after breast-conservation treatment for early-stage breast cancer.

    abstract:BACKGROUND:Recent studies have shown that breast cancer detected by screening has a more favorable prognosis than interval breast cancer. To further understand the biologic significance of this finding, we investigated the association of disease recurrence, local and distant, with the method of detection of the primary...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2008.n.014

    authors: Tchou J,Greshock J,Bergey MR,Sonnad SS,Sargen M,Weinstein S,Czerniecki BJ,Boraas M,Fraker DL,Rosato E,Fox K,Weber B,Solin LJ

    更新日期:2008-04-01 00:00:00

  • Nipple Discharge After Nipple-Sparing Mastectomy With and Without Associated Pregnancy.

    abstract:BACKGROUND:Nipple-sparing mastectomies (NSMs) preserve the intact nipple, including nipple duct orifices. Retained orifices might remain patent and communicate with the underlying reconstruction. We report the incidence and outcomes of nipple discharge after NSM in pregnant and nonpregnant women. PATIENTS AND METHODS:...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2019.03.003

    authors: Tang R,Kelly BN,Smith BL,Lanahan CR,Brown CL,Gadd MA,Hughes KS,Oseni TO,McGugin C,Specht MC,Coopey SB

    更新日期:2019-08-01 00:00:00

  • Rheumatic disorders and functional disability with aromatase inhibitor therapy.

    abstract:BACKGROUND:Aromatase inhibitor therapy is often effective for breast cancer, yet it can be accompanied by musculoskeletal pain and stiffness. This prevalence assessment aimed to characterize a rheumatologist's view of frequency and clinical features, including associated disability, within a breast cancer clinic panel ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2010.n.019

    authors: Moxley G

    更新日期:2010-04-01 00:00:00

  • Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients?

    abstract:OBJECTIVE:The Hungarian National Institute of Oncology has just closed a single-center randomized clinical study. The Optimal Treatment of the Axilla-Surgery or Radiotherapy (OTOASOR) trial compares completion axillary lymph node dissection (cALND) with regional nodal irradiation (RNI) in patients with sentinel lymph n...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clbc.2013.04.004

    authors: Sávolt A,Polgár C,Musonda P,Mátrai Z,Rényi-Vámos F,Tóth L,Kásler M,Péley G

    更新日期:2013-10-01 00:00:00

  • Markers of Cardiotoxicity in Early Breast Cancer Patients Treated With a Hypofractionated Schedule: A Prospective Study.

    abstract:PURPOSE:To evaluate, in a series of early breast cancer (BC) patients treated with hypofractionated adjuvant radiotherapy (RT), whether N-terminal-pro hormone B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I assay measurements can predict acute clinical or preclinical cardiotoxicity. PATI...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.09.005

    authors: De Sanctis V,Alfò M,Vitiello C,Vullo G,Facondo G,Marinelli L,Burocchi S,Gallo G,Valeriani M,Campanella B,Scalabrino G,Russo I,Salerno G,Cardelli P,Osti MF,De Biase L

    更新日期:2020-09-10 00:00:00

  • The Role of Contrast-Enhanced Ultrasound in the Diagnosis and Pathologic Response Prediction in Breast Cancer: A Meta-analysis and Systematic Review.

    abstract:PURPOSE:To determine the overall performance of contrast-enhanced ultrasound (CEUS) in differentiating between benign and malignant breast lesions and in predicting the pathologic response to neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC). MATERIALS AND METHODS:Articles published up to April 2019 w...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.03.002

    authors: Zhou SC,Le J,Zhou J,Huang YX,Qian L,Chang C

    更新日期:2020-08-01 00:00:00

  • Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer.

    abstract::Breast cancer is the second leading cause of cancer death in women, affecting 1.7 million patients every year worldwide. As a result of its heterogeneous nature, the genetic profile and associated clinical feature varies greatly among different breast cancer subtypes. With the advancement of molecular biology, our und...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2016.05.012

    authors: Tang Y,Wang Y,Kiani MF,Wang B

    更新日期:2016-10-01 00:00:00

  • Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy.

    abstract::More than 220,000 women will be diagnosed with breast cancer this year, and approximately 75% of these women will be long-term survivors of this disease. Survival has improved largely because of advances in adjuvant hormone therapy and chemotherapy, as well as early detection strategies. Because most women will receiv...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2007.s.003

    authors: Rugo HS

    更新日期:2007-07-01 00:00:00

  • Synchronous carcinoma and lymphoma of the breast.

    abstract::Primary breast lymphoma is a rare entity. Furthermore, extranodal marginal zone B-cell lymphoma affecting the breast is exceedingly rare. We report a unique case of invasive lobular carcinoma diagnosed simultaneously with an extranodal marginal zone B-cell lymphoma of the breast. A literature review demonstrated 2 rep...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2008.n.033

    authors: Anavekar NS,Rozen WM,Rowe K,Murphy C

    更新日期:2008-06-01 00:00:00

  • Neoadjuvant endocrine therapy in primary breast cancer.

    abstract::Neoadjuvant chemotherapy has been employed increasingly in operable breast cancer during recent years. Several randomized trials showed that the chances of breast conserving therapy are being enhanced, and that survival was not compromised by primary systemic therapy compared to adjuvant treatment. Apart from the surg...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2004.n.039

    authors: Huober J,Krainick-Strobel U,Kurek R,Wallwiener D

    更新日期:2004-12-01 00:00:00